Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)

Mehdi Touat, Giuseppe Lombardi, Patrizia Farina, Michel Kalamarides, Marc Sanson

Research output: Contribution to journalArticle

Abstract

Background: Meningiomas are the most frequent primary brain tumor in adults. Evidence suggests that female sex hormones play a role in the meningioma tumorigenesis. In particular, progesterone, has a receptor (PR) that is highly expressed in the majority of grade I meningiomas. Multiple meningiomas (diffuse meningiomatosis) are less frequent, but have a higher female predominance and a higher PR expression. They are, therefore, attractive candidates for anti-PR therapy.

Methods: We treated three consecutive women with multiple meningiomas with mifepristone (RU 486). It is a synthetic steroid with high affinity for both progesterone and glucocorticoid receptors.

Results: The treatment was well tolerated, and we observed an important and long-lasting clinical (3/3) and radiological response (2/3) or stabilisation. All the three patients are now stable after five to nine years of treatment.

Conclusions: These encouraging results strongly support a prospective clinical trial in this preselected population.

Original languageEnglish
Pages (from-to)1831-1835
Number of pages5
JournalActa Neurochirurgica
Volume156
Issue number10
DOIs
Publication statusPublished - 2014

Keywords

  • hormonotherapy
  • Meningiomas
  • Progesterone
  • RU486

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)'. Together they form a unique fingerprint.

  • Cite this